FRAGMIN 18000 UNIT / 0.72 ML — DIN 02352680
DALTEPARIN SODIUM : 18000 UNIT / 0.72 ML · PFIZER CANADA ULC · SOLUTION · wholesale supply in Canada
Health Canada status: MARKETED
What is FRAGMIN?
FRAGMIN 18000 UNIT / 0.72 ML contains DALTEPARIN SODIUM : 18000 UNIT / 0.72 ML. It is listed in the Health Canada Drug Product Database under DIN 02352680, held by PFIZER CANADA ULC, supplied as SOLUTION for INTRAVENOUS ; SUBCUTANEOUS administration. Health Canada currently lists it as marketed, status dated 01-Feb-2011. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is FRAGMIN used for?
Fragmin (dalteparin sodium injection) is indicated for: • Thromboprophylaxis in conjunction with surgery • Treatment of acute deep venous thrombosis • Unstable coronary artery disease (UCAD), i.e., unstable angina and non - Q - wave myocardial infarction • Prevention of clotting in the extracorporeal system during hemodialysis and hemofiltration in connection with acute renal failure or chronic renal insufficiency • Extended treatment of symptomatic venous thromboembolism (VTE) to prevent recurrence of venous thromboembolism in patients with cancer • Reduction of deep vein thrombosis (DVT) in hospitalized patients with severely restricted mobility during acute illness.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
How much does Dalteparin cost around the world?
Dalteparin is listed on 3 of the national price registers Nexara ingests. Each country publishes on a different basis, so those figures are not comparable with one another — or with a Canadian wholesale price.
What a market publishes matters more than the number it publishes. Austria publishes a KVP (Kassenverkaufspreis); Romania publishes a max producer price; South Africa publishes a single exit price. Comparing an ex-factory ceiling against a pharmacy public price tells you nothing about either, and comparing either against a Canadian landed cost tells you less.
| Market | Price basis published there | Brands | Packs listed | Range |
|---|---|---|---|---|
| Austria | KVP (Kassenverkaufspreis) | 9 | 11 | EUR███.██ |
| South Africa | single exit price | 6 | 6 | ZAR███.██ |
| Romania | max producer price | 1 | 1 | RON███.██ |
18 pack listings across 16 brand entries and 3 price bases, refreshed 03 Sep 2026. Ranges span every Dalteparin pack in that market, so a high figure is usually a larger pack rather than the same product.
Canada publishes no comparable public list price. For a delivered Canadian price on a licensed account, verify your licence — it takes about a minute.
Is there a generic Dalteparin in Canada, and who makes it?
Every market authorization holder with a Canadian DIN for this molecule, and how many of their listings Health Canada currently shows as marketed.
2 holders have a Canadian DIN containing Dalteparin, across 13 DINs, of which 10 are currently marketed. Marketed count is the number that matters: an approval that is not marketed cannot be bought.
| Market authorization holder | DINs | Marketed | Brand names | Position |
|---|---|---|---|---|
| PFIZER CANADA ULC | 12 | 10 | FRAGMIN | Sourceable in Canada |
| PHARMACIA & UPJOHN INC | 1 | 0 | FRAGMIN INJ.-LIQ 2500 IU(ANTI-XA)/ML | No marketed DIN |
Health Canada’s Drug Product Database does not flag which listing is the originator and which are subsequent-entry products, so Nexara does not label them here. Interchangeability is determined provincially, not federally — confirm for your province before a formulary switch. Nexara can confirm which of these is actually obtainable, and on what lead time, per order.
How is it supplied and stored?
Pack configuration, storage class and the handling constraints that drive cold-chain planning. One DIN can cover more than one pack size, and the pack — not the DIN — is what gets priced, shipped and invoiced.
| Strength on the label | 18000 UNIT / 0.72 ML |
|---|---|
| Dosage form | SOLUTION |
| Route | INTRAVENOUS ; SUBCUTANEOUS |
| Pack configuration (monograph) | Solution for injection, 25 000 IU (anti - factor Xa)/mL, 3.8 mL multi - dose vial, package of 1. Solution for injection, 2 500 IU (anti - factor Xa)/0.2 mL, single dose 0.5 mL syringe*, package of 10. Solution for injection, 3 500 IU (anti - factor Xa)/0.28 mL, single dose 0.5 mL syringe*, package of 10. Solution for injection, 5 000 IU (anti - factor Xa)/0.2 mL, single dose 0.5 mL syringe*, package of 10. Solution for injection, 7 500 IU (anti - factor Xa)/0.3 mL, single dose 0.5 mL syringe*, package of 5. Solution for injection, 10 000 IU (anti - factor Xa)/0.4 mL, single dose 1 mL syringe*, package of 5. Solution for injection, 12 500 IU (anti - factor Xa)/0.5 mL, single dose 1 mL syringe*, package of 5. Solution for injection, 15 000 IU (anti - factor Xa)/0.6 mL, single dose 1 mL syringe*, package of 5. Solution for injection, 16 500 IU (anti - factor Xa)/0.66 mL, single dose 1 mL syringe*, package of 5. Solution for injection, 18 000 IU (anti - factor Xa)/0.72 mL, single dose 1 mL syringe*, package of 5. |
| Storage | null |
Before an order line is unambiguous Nexara needs the strength, the pack size and the presentation, because this listing covers more than one of them.
Substance and classification
| Active substance | Dalteparin |
|---|---|
| ATC code | B01AB04 |
| AHFS class | 20:12.04.16 |
| Biosimilar biologic | No |
Health Canada record and identifiers
The regulatory facts straight from the Drug Product Database, plus every identifier form Nexara accepts on a purchase order. A DIN written without its leading zeros is the commonest reason an order line fails to match.
| DIN (8-digit, as used in ordering) | 02352680 |
|---|---|
| DIN (unpadded, as printed on some documents) | 2352680 |
| Brand name | FRAGMIN |
| Generic / active ingredient | DALTEPARIN SODIUM : 18000 UNIT / 0.72 ML |
| Market authorization holder | PFIZER CANADA ULC |
| Health Canada schedule | Prescription |
| ATC code | B01AB04 |
| ATC anatomical main group | B — Blood and blood-forming organs |
| ATC therapeutic subgroup | B01AB |
| Current status | MARKETED |
| Status date | 01-Feb-2011 |
| Original market date | 2011-02-01 00:00:00 |
| Status source | Live Health Canada DPD sync |
Verify on the primary sources
What can be used instead?
Alternatives on every axis a buyer actually considers — the same molecule in another presentation, the same class, an adjacent class, or a fixed-dose combination. Every row is led by the marketed DIN count, because that is what can be bought this week.
1 · Same molecule, other Canadian presentations
10 of 13 Canadian DINs for this molecule are currently marketed. Marketed products are listed first.
| Product | Strength | Form | Holder | Health Canada status | DIN |
|---|---|---|---|---|---|
| FRAGMIN | 16500 UNIT / 0.66 ML | SOLUTION | PFIZER CANADA ULC | MARKETED | 02494582 |
| FRAGMIN | 5000 UNIT / 0.2 ML | SOLUTION | PFIZER CANADA ULC | MARKETED | 02132648 |
| FRAGMIN | 15000 UNIT / 0.6 ML | SOLUTION | PFIZER CANADA ULC | MARKETED | 02352672 |
| FRAGMIN | 3500 UNIT / 0.28 ML | SOLUTION | PFIZER CANADA ULC | MARKETED | 02430789 |
| FRAGMIN | 2500 UNIT / 0.2 ML | SOLUTION | PFIZER CANADA ULC | MARKETED | 02132621 |
| FRAGMIN | 25000 UNIT | SOLUTION | PFIZER CANADA ULC | MARKETED | 02231171 |
| FRAGMIN | 7500 UNIT / 0.3 ML | SOLUTION | PFIZER CANADA ULC | MARKETED | 02352648 |
| FRAGMIN | 10000 UNIT / 0.4 ML | SOLUTION | PFIZER CANADA ULC | MARKETED | 02352656 |
| FRAGMIN | 12500 UNIT / 0.5 ML | SOLUTION | PFIZER CANADA ULC | MARKETED | 02352664 |
| FRAGMIN | 10000 UNIT | SOLUTION | PFIZER CANADA ULC | CANCELLED POST MARKET | 02132664 |
2 · Same class — other molecules in ATC B01AB
| Molecule | Canadian brands | DINs | Marketed | Sourceable |
|---|---|---|---|---|
| Enoxaparin | AXBERI · AXBERI HP · ELONOX · ELONOX HP · INCLUNOX · INCLUNOX HP · LOVENOX · LOVENOX HP · LOVENOX WITH PRESERVATIVE 300MG/3ML · NOROMBY · NOROMBY HP · REDESCA · REDESCA HP | 46 | 44 | Yes |
| Tinzaparin | INNOHEP · INNOHEP DISP.SYR.-11700 ANTI-XA IU/ML · LOGIPARIN LIQ SC 10000 FXAIU/ML | 13 | 11 | Yes |
| Heparin | CALCILEAN INJ 20000UNIT/0.8ML · CALCIPARINE INJ 20000IU/AMP · CALCIPARINE INJ 5000IU · HEPALEAN 10,000 USP · HEPALEAN 1000 USP · HEPALEAN 25,000 USP · HEPALEAN-LOK 10 USP · HEPALEAN-LOK 100 USP · HEPARIN LEO 100UNIT/ML · HEPARIN LEO INJ 10000UNIT/ML · HEPARIN LEO INJ 1000UNIT/ML · HEPARIN LEO INJ 25000UNIT/ML · HEPARIN LOCK FLUSH SOLUTION INJECTION USP · HEPARIN SODIUM 20000UNIT/500ML IN DEXT 5% INJ · HEPARIN SODIUM 25000UNIT/500ML IN 5% DEXTR INJ · HEPARIN SODIUM 5000UNIT/500ML IN SODIUM CHLORIDE 0.9% · HEPARIN SODIUM IN 0.9% SODIUM CHLORIDE INJECTION · HEPARIN SODIUM INJECTION USP · HEPARIN SODIUM INJECTION USP (SINGLE USE VIAL-PRESERVATIVE FREE) · HEPARIN SODIUM INJECTION USP (MULTIDOSE VIAL-WITH PRESERVATIVE) · HEPARIN SODIUM INJECTION, USP | 32 | 10 | Yes |
| Dalteparin | FRAGMIN · FRAGMIN INJ.-LIQ 2500 IU(ANTI-XA)/ML | 13 | 10 | Yes |
| Heparin, Combinations | HEPARIN SOD AND 0.9% SOD CHLORIDE INJ · HEPARIN SODIUM & 5% DEXTROSE INJECTION LIQ · HEPARIN SODIUM & DEXTROSE 5% IN VIAFLEX LIQ · HEPARIN SODIUM 20000UNITS IN 5% DEXTROSE INJ · HEPARIN SODIUM 25000UNITS IN 5% DEXTROSE INJ · HEPARIN SODIUM AND DEXTROSE 5% INJ USP · HEPARIN SODIUM IN 0.9% SODIUM CHLORIDE INJECTION · HEPARIN SODIUM IN 5% DEXTROSE INJECTION, 25000UNIT/500ML | 8 | 4 | Yes |
| Antithrombin | ANTITHROMBIN III IMMUNO · ANTITHROMBIN III NF · THROMBATE III · THROMBATE III PWS IV 1000IU/VIAL · THROMBATE III PWS IV 500IU/VIAL | 7 | 2 | Yes |
| Danaparoid | ORGARAN | 1 | 1 | Yes |
| Nadroparin | FRAXIPARINE · FRAXIPARINE FORTE | 8 | 0 | Not in Canada |
A molecule with zero marketed DINs cannot be sourced domestically, however many approvals it holds — if one of these sits on a formulary or in an older protocol, that is the line to check.
3 · Adjacent classes in ATC B01A
| ATC subgroup | Molecules | DINs | Marketed |
|---|---|---|---|
| B01AF | Apixaban · Edoxaban · Rivaroxaban | 159 | 121 |
| B01AC | Abciximab · Acetylsalicylic Acid · Cangrelor · Clopidogrel · Combinations · Dipyridamole · Epoprostenol · Eptifibatide · Prasugrel · Selexipag · Ticagrelor · Ticlopidine · Tirofiban · Treprostinil · Vorapaxar | 158 | 66 |
| B01AA | Acenocoumarol · Warfarin | 62 | 16 |
| B01AE | Argatroban · Bivalirudin · Dabigatran Etexilate · Lepirudin | 18 | 11 |
| B01AX | Caplacizumab · Defibrotide · Fondaparinux | 10 | 5 |
| B01AD | Alteplase · Ancrod · Anistreplase · Drotrecogin Alfa · Reteplase · Streptokinase · Tenecteplase · Urokinase | 22 | 4 |
Not clinical advice. These tables describe what can be supplied in Canada, not what should be prescribed. Substitution within or across classes is a prescriber and pharmacist decision, and interchangeability is determined provincially.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address. Patients and unlicensed buyers are routed to a partner pharmacy.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Why is there no price on this page?
Nexara quotes a delivered Canadian price per order, against a verified licence. Foreign list prices are published on incompatible bases and are not a guide to what any buyer can obtain here, so this page shows which markets list the molecule and on what basis, and nothing more.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.